Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10825311rdf:typepubmed:Citationlld:pubmed
pubmed-article:10825311lifeskim:mentionsumls-concept:C0020649lld:lifeskim
pubmed-article:10825311lifeskim:mentionsumls-concept:C0029276lld:lifeskim
pubmed-article:10825311lifeskim:mentionsumls-concept:C1538703lld:lifeskim
pubmed-article:10825311lifeskim:mentionsumls-concept:C0205246lld:lifeskim
pubmed-article:10825311lifeskim:mentionsumls-concept:C0002913lld:lifeskim
pubmed-article:10825311lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:10825311lifeskim:mentionsumls-concept:C1523987lld:lifeskim
pubmed-article:10825311pubmed:issue6lld:pubmed
pubmed-article:10825311pubmed:dateCreated2000-6-16lld:pubmed
pubmed-article:10825311pubmed:abstractTextWe sought to evaluate the efficacy and side effect profile of a small dose of ornipressin, a vasopressin agonist specific for the V1 receptor, administered to reverse the hypotension associated with combined general/epidural anesthesia. A total of 60 patients undergoing intestinal surgery were studied. After the induction of anesthesia, 7-8 mL of bupivacaine 0.5% with 2 microg/kg clonidine and 0.05 microg/kg sufentanil after an infusion of 5 mL of bupivacaine 0.06% with 0.5 microg x kg(-1) x h(-1) clonidine and 0.1 microg/h of sufentanil were administered by an epidural catheter placed at T7-8 vertebral interspace. When 20% reduction of baseline arterial blood pressure developed, patients were randomly assigned to receive, in a double-blinded design, dopamine started at 2 microg x kg(-1) x min(-1), norepinephrine started at 0.04 microg x kg(-1) x min(-1), or ornipressin started at 1 IU/h. Fifteen patients presenting without hypotension were used as control subjects. Beside routine monitoring, S-T segment analysis, arterial lactacidemia, and gastric tonometry were performed. Ornipressin restored arterial blood pressure after 8 +/- 2 vs 7 +/- 3 min in the norepinephrine group and 11 +/- 3 min in the dopamine group (P < 0.05). This effect was achieved with 2 IU/h of ornipressin in most of the patients (11 of 15). Ornipressin did not induce any modification of the S-T segment; however, it significantly increased intracellular gastric PCO(2) (P < 0.05), indicating splanchnic vasoconstriction. Implications: In the population studied, small-dose ornipressin was effective to restore arterial blood pressure without causing major ischemic side effects.lld:pubmed
pubmed-article:10825311pubmed:languageenglld:pubmed
pubmed-article:10825311pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825311pubmed:citationSubsetAIMlld:pubmed
pubmed-article:10825311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825311pubmed:statusMEDLINElld:pubmed
pubmed-article:10825311pubmed:monthJunlld:pubmed
pubmed-article:10825311pubmed:issn0003-2999lld:pubmed
pubmed-article:10825311pubmed:authorpubmed-author:LaterreP FPFlld:pubmed
pubmed-article:10825311pubmed:authorpubmed-author:De KockMMlld:pubmed
pubmed-article:10825311pubmed:authorpubmed-author:Lavand'hommeP...lld:pubmed
pubmed-article:10825311pubmed:authorpubmed-author:AndruettoPPlld:pubmed
pubmed-article:10825311pubmed:authorpubmed-author:VanderessenLLlld:pubmed
pubmed-article:10825311pubmed:authorpubmed-author:DekromSSlld:pubmed
pubmed-article:10825311pubmed:authorpubmed-author:VanderickBBlld:pubmed
pubmed-article:10825311pubmed:issnTypePrintlld:pubmed
pubmed-article:10825311pubmed:volume90lld:pubmed
pubmed-article:10825311pubmed:ownerNLMlld:pubmed
pubmed-article:10825311pubmed:authorsCompleteYlld:pubmed
pubmed-article:10825311pubmed:pagination1301-7lld:pubmed
pubmed-article:10825311pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:meshHeadingpubmed-meshheading:10825311...lld:pubmed
pubmed-article:10825311pubmed:year2000lld:pubmed
pubmed-article:10825311pubmed:articleTitleOrnipressin (Por 8): An efficient alternative to counteract hypotension during combined general/epidural anesthesia.lld:pubmed
pubmed-article:10825311pubmed:affiliationDepartment of Anesthesiology, University of Louvain, St. Luc Hospital, Brussels, Belgium. dekock@anes.ucl.ac.belld:pubmed
pubmed-article:10825311pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10825311pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:10825311pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:10825311pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10825311lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10825311lld:pubmed